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Abstract
The data on the effect of smoking on non-alcoholic fatty liver disease (NAFLD) has been 
controversial. The aim of this study was to investigate if an association exists between serum 
cotinine level (a tobacco biomarker) and NAFLD prevalence in the general US population. We 
conducted a crosssectional analysis of data from the Third National Health and Nutrition 
Examination Survey (NHANES III). We included 11,003 adults aged 20–74 years who underwent 
ultrasonography. Of those, 4036 were identified as having NAFLD and 6967 were recognized as 
controls. The percentage of current smokers was significantly lower in subjects with NAFLD 
compared with those in controls (21.5% vs 26.0%, p<0.01). After adjustment for potential 
confounders, there was no association between current or former smokers with NAFLD. 
Additionally, no associations were observed between the levels of serum cotinine and NAFLD. No 
association between serum cotinine levels at each quartile level and NAFLD was observed 
regardless of smoking status. In this large US population-based study, we did not find an 
association between NAFLD and self-reported smoking status or measured serum cotinine level.
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INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases 
worldwide.1 It comprises the spectrum of fatty liver diseases including simple steatosis, 
steatohepatitis, and cirrhosis.1 In a sense, NAFLD represents another component of 
metabolic syndrome (MetS)23 since not only is obesity a shared major risk factor but 
decreased insulin sensitivity is also commonly observed in both. Additionally, the strong 
association of NAFLD with features of MetS4 such as obesity, central fat distribution, 
diabetes, dyslipidemia, and hypertension, provide further support for this hypothesis. Several 
reports and a meta-analysis have demonstrated smoking contributes to MetS.5–7 Slagter et 
al7 investigated the relationship between smoking and the individual components of MetS. 
The most notable differences between smokers and non-smokers were observed in the levels 
of high-density lipoprotein (HDL) and triglycerides. This finding was seen in men and 
women, irrespective of their body mass index (BMI).7 Since MetS is a known risk factor for 
NAFLD, several studies were conducted to determine the association between smoking and 
NAFLD. However, the results have been conflicting.89 In a community-based study of 8580 
Chinese subjects, the authors found that both passive and heavy active smoking were 
associated with NAFLD.9 Conversely, no association was observed in a cross-sectional study 
from Mexico in which the routine health examination results from 933 subjects were 
examined.8
A plausible explanation for these contradicting results could lie in the reliability of the 
questionnaire used to determine smoking status.1011 Smoke exposure can be assessed with 
levels of serum cotinine, which is a metabolite of nicotine often applied as a surrogate 
measurement of smoke exposure due to its longer half-life than nicotine.12 The half-life of 
cotinine is about 24 hours compared with nicotine’s half-life of 30 min.12 Its levels, when 
use with in combination with self-reported status, can confirm the history of smoke 
exposure.
As part of the Third National Health and Nutrition Examination Survey (NHANES III), 
ultrasonographic examinations of the abdomen were performed and the presence or absence 
of hepatic steatosis was determined through a standardized algorithm.13 Given the 
conflicting association between NAFLD and smoking as demonstrated by the 
aforementioned self-reported questionnaires, we conducted this population-based study 
using data from NHANES III, with a focus on levels of serum cotinine, to further clarify the 
relationship between these two conditions.
METHODS
The Third National Health and Nutrition Examination Survey
The NHANES III (1988–1994) is a complex, multistage, stratified, clustered, probability 
sample study designed to obtain information regarding nutritional status and health of the 
US population.14 The survey included questionnaires, physical examination, and laboratory 
tests. The study was approved by the Center for Disease Control and Prevention’s 
Institutional Review board.
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Study population
During the survey period, 16,115 subjects who were 20–74 years old completed the 
interview, physical examination, laboratory tests, and liver ultrasound examination. After 
excluding subjects without ultrasound images and those with ungradable degree of hepatic 
steatosis from ultrasound (n=2259), a total of 13,856 subjects were eligible for further study. 
We also excluded 2852 subjects with hepatic conditions other than NAFLD (ie, alcoholic 
liver disease, viral hepatitis, iron overload) and one subject without smoking status 
information. A total of 11,003 participants constituted the study cohort (figure 1).
Data collection
Baseline demographic data on age, race or ethnicity, sex, income, and education level were 
obtained using a questionnaire. Information on alcohol consumption, smoking, underlying 
medical conditions, physical activity, and drug use was obtained in a household interview. 
During the physical examination, height and body weight were measured and BMI was 
calculated. Blood pressure was recorded either at the household interview or during physical 
examination.
Race or ethnicity was categorized as ‘non-Hispanic blacks’, ‘non-Hispanic whites’, 
‘Mexican-American’, and ‘others’. Education was categorized as ≤8, 9 to 12, and ≥12 years, 
based on completed years of schooling. Economic status was categorized as ≤$15,000, 
$15,001 to $25,000, and ≥$25,000, according to the household income.
Smoking status was categorized as ‘never’, ‘current’, and ‘former’. Current smokers were 
those who smoked daily or occasionally and reported having smoked more than 100 
cigarettes in their lifetime. Former smokers were defined as those who reported having 
smoked >100 cigarettes during their lifetime but no longer smoked at all at the time of 
enrollment. Those who smoked <100 cigarettes during their lifetime were classified as 
‘having never smoked’.15 Heavy alcohol use was defined as an average of >20 g/day for men 
and >10 g/day for women.16
Physical activity was calculated based on a self-reported history of participating in one of 
the following activities during the past month: swimming, jogging, walking, running, 
aerobics, bicycling, weight lifting, and any gardening/yard work, dancing, and calisthenics. 
Based on the information, a physical activity intensity score was calculated using the ratio of 
metabolic rate achieved during physical activity compared with that during resting. The 
physical activity intensity score was then categorized as inactive (score ≤3.5), moderately 
active (score 3.6–14.9), and active (score ≥15.0).17
Insulin resistance was defined by a homeostasis of model assessment score >3.0.18 Elevated 
serum aminotransferases was defined as alanine aminotransferase (ALT) >40 U/L or 
aspartate aminotransferase (AST) >37 U/L (for men), and ALT or AST>31 U/L (for 
women). Transferrin saturation was considered to be elevated when its level was ≥50%.19 
Serum cotinine levels were measured using an isotope dilution, liquid chromatography, and 
tandem mass spectrometry method. The limit of detection using this method is 0.05 ng/mL. 
Subjects with serum cotinine levels below the limit of detection were assigned a level of 
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0.035 ng/mL. In our study, serum cotinine levels were determined and divided into quartiles 
for each smoking status (never-smokers, former smokers, and current smokers).
Definitions of NAFLD and controls
Ultrasonography examinations of the liver and gallbladder were performed in participants 
aged 20–74 years with a Toshiba (Tustin, California, USA) SSA-90A machine using a 3.75 
and 5.0 MHz transducer.13 The liver was graded as normal, mild, moderate, or severe 
hepatic steatosis based on the following information: (1) Degree of the brightness of liver 
parenchyma, (2) Presence of liver-to-kidney contrast, (3) Presence of echogenic walls in the 
small intrahepatic vessels, (4) Presence of deep beam attenuation, and (5) Definition of the 
gallbladder walls.13
In the absence of a consensus definition, NAFLD in our study was defined as the presence of 
mild-to-severe hepatic steatosis on ultrasonography without other causes of chronic liver 
diseases (such as iron overload, defined by transferrin saturation ≥50%, positive hepatitis B 
and C serology, and heavy alcohol consumption). Healthy controls were defined as those 
without any evidence of steatosis on ultrasonography and any evidence of chronic liver 
diseases.
Statistical analyses
All analyses were weighted to account for unequal probabilities of selection, based on the 
complexity of the survey data and the study design. Demographic and clinical differences 
among study participants according to smoking status were compared using the one-way 
analysis of variance or χ2 test, as appropriate. Serum cotinine was log-transformed to reduce 
the skewness in its distribution. Unconditional multivariate logistic regression was used to 
assess the association between smoking status/serum cotinine and NAFLD. The first model 
included age, sex, ethnicity, socioeconomic status, BMI, and physical activity. The second 
model included age, sex, ethnicity, socioeconomic status, BMI, physical activity, insulin 
resistance, systolic/diastolic blood pressure, and serum triglycerides and HDL. We also 
conducted stratified analyses based on self-reported smoking status. All analyses were 
performed using SAS V.9.3 (SAS Institute, Cary, North Carolina, USA). A p value ≤0.05 
(two-sided) was considered statistically significant.
RESULTS
Demographic and clinical characteristics of the study participants
The schematic diagram on the selection of participants is shown in figure 1. Of the 11,003 
participants included in the main analyses, 4036 (37%) were identified as having NAFLD 
and 6967 (63%) as controls. Subjects with NAFLD were older (48.5 vs 43 years, p<0.01), 
had higher systolic (129.1 vs 121.6 mm Hg, p<0.01) and diastolic (77.1 vs 73.5 mm Hg, 
p<0.01) blood pressures; higher serum triglycerides (2.2 vs 1.5 mmol/L, p<0.01), higher 
total cholesterol (5.5 vs 5.3 mmol/L, p<0.01), higher circulating glycosylated hemoglobin 
(6.0% vs 5.5%, p<0.01), higher serum AST (24.4 vs 20.1 U/L, p<0.01), and higher serum 
ALT (23.5 vs 15.7 U/L, p<0.01). Subjects with NAFLD were more likely to be men (53.1% 
vs 41.6%, p<0.01), obese (49.5% vs 22.4%, p<0.01), and Mexican-American (38.5% vs 
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28%, p<0.01). Selected demographic and clinical characteristics stratified by smoking status 
are summarized in table 1. Severe hepatic steatosis was found in 7%, 9.9%, and 5.8% among 
non-smokers, former smokers, and current smokers, respectively (p<0.01).
Association between smoking status, serum cotinine levels and NAFLD
Using the questionnaires, 51.1% and 27.5% of NAFLD subjects were non-smokers and 
former smokers, respectively; whereas 53.1% of controls were non-smokers and 20.9% were 
former smokers. The percentage of current smokers was significantly lower in subjects with 
NAFLD compared with those in controls (21.5% vs 26.0%, p<0.01). The medians of serum 
cotinine levels were 0.32 ng/mL in those with NAFLD and 0.37 ng/mL in controls (p<0.01; 
table 2).
Associations of self-reported smoking status and serum cotinine levels with NAFLD are 
summarized in table 2. After adjustment for potential confounders in the model 1, there was 
no association between current (OR 0.92, 95% CI 0.83 to 1.03) and former smokers (OR 
1.11, 95% CI 0.99 to 1.24) with NAFLD. No associations were observed between the levels 
of serum cotinine (OR 1.000, 95% CI 0.999 to 1.000) or its log-transformed levels (OR 
0.991, 95%CI 0.977 to 1.006) with NAFLD. Similar results were observed in the model 2 
(table 2).
The association of serum cotinine divided by quartile levels and NAFLD, stratified by 
smoking status is shown in table 3. No association between serum cotinine levels at each 
quartile level and NAFLD was observed regardless of smoking status in the logistic 
regression analyses for both models. The trend analysis demonstrated the inverse association 
between serum cotinine levels and NAFLD among current smokers (p for trend <0.01).
DISCUSSION
In this population-based study, we found no association between NAFLD with self-reported 
smoking status and serum cotinine level. Active tobacco smoking is a known risk factor for 
several chronic diseases such as cancer, cardiovascular disease, and diabetes.20–22 Smoking 
also has an impact on liver diseases as it has shown to be a risk factor for advanced fibrosis 
in those with hepatitis C infection.23 The long-term morbidity and mortality from chronic 
hepatitis C infection are expected to decline due to highly effective, direct-acting antiviral 
agents.24 However, the health and economic burdens from NAFLD will continue due to the 
worsening epidemics of obesity and MetS.25 Therefore, identification of risk-modifying 
factors associated with NAFLD is of the utmost importance, as it may have an impact on the 
natural course of this disease.
MetS, through a combination of unfavorable health factors such as dyslipidemia, visceral 
obesity, and hypertension, is strongly associated with NAFLD. Smoking has also been 
associated with MetS.5726 Tobacco use is associated with increasing waist circumference, 
dyslipidemia, and hypertension which suggests a role for smoking on insulin resistance.52728 
A recent population-based study of 59,467 individuals showed that smoking is associated 
with a higher risk of MetS in both genders and in all BMI classes.7 Moreover, the increased 
risk was stronger for heavy smokers but not as significant among light and former smokers.7
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Given the link between smoking and MetS, a known risk factor for NAFLD, several 
previous studies attempted to determine the relationship between smoking and NAFLD.89 A 
study from China observed a positive association between active smoking and NAFLD.9 
Furthermore, active tobacco smoking and an elevated BMI had a synergistic effect on 
NAFLD prevalence.9 However, another study from Mexico found contradicting results.8 It is 
important to note these studies used the self-reported questionnaires to determine the 
smoking status of the participants. In our study, we found self-reported former smokers had 
a mean serum cotinine level of 24.6 ng/mL. Therefore, there exists the concern of reporting 
bias that participants may tend to report less than the amount they actually smoke. It is 
important to note that we observed that among current smokers, the prevalence of NAFLD 
was lower in subjects with higher levels of cotinine (OR 0.62, 95% CI 0.49 to 0.79) in the 
crude analysis. This finding is likely due to significantly lower BMI among NAFLD subjects 
with serum cotinine in the fourth quartile range (25.2±5.0 kg/m2) than that in the first 
quartile (27.8±6.1 kg/m2, p<0.01). However, in the multivariate analyses adjusting for 
potential confounders, we found no association between serum cotinine levels at each 
quartile level and NAFLD.
NHANES III provided an opportunity for detailed analysis on the relationships between 
tobacco smoking and NAFLD. First, this is a population-based study representing the US 
population. It included comprehensive information on anthropometric measurements, 
laboratory results, and abdominal ultrasound and, thus, allowed us to determine the presence 
of MetS as well as NAFLD. Additionally, the use of self-reported questionnaires with 
NHANES III provided objective evidence of smoking exposure with levels of serum 
cotinine, a metabolite of nicotine which can be used as a marker of smoke exposure due to 
its longer half-life than nicotine.12 In this population-based study, we found no association 
between NAFLD with self-reported smoking status and serum cotinine level. It is known 
that the overall lifestyle of smokers is generally different from that of non-smokers.29 
Despite the adjustments for physical activity in our analyses, we still did not find an 
association between smoking exposure and NAFLD.
In conclusion, in this large US population-based study, we did not find a relationship 
between NAFLD and self-reported smoking status or serum cotinine levels. Despite the 
strength of the sample size and the study cohort representing the US population, we 
acknowledge several limitations. NHANES III does not provide histological data which 
limited our ability to further categorize NAFLD by histological subtypes. Furthermore, 
ultrasound is not the most sensitive modality to characterize steatosis or diagnose NAFLD. 
However, it is the most practical screening modality for a large population-based study when 
obtaining liver biopsies is not feasible. Though we failed to demonstrate smoking as a 
possible risk-modifying factor associated with NAFLD, tobacco smoking is a well-known 
risk factor for several chronic diseases such as cancer, cardiovascular disease, and diabetes. 
Thus, interventions to promote successful smoking cessation should still be implemented as 
preventative measures.
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Significance of this study
What is already known about this subject?
► Non-alcoholic fatty liver disease (NAFLD) is associated with obesity and 
metabolic syndrome.
► Several reports and a meta-analysis have shown that smoking is linked to 
metabolic syndrome.
► The association between smoking and NAFLD is debatable.
What are the new findings?
► In this large US population-based study, we did not find an association 
between NAFLD and self-reported smoking status or measured serum 
cotinine level.
How might these results change the focus of research or clinical practice?
► Though we failed to demonstrate smoking as a possible risk-modifying factor 
associated with NAFLD, tobacco smoking is a known risk factor for several 
chronic diseases such as cancer, cardiovascular disease, and diabetes. Thus, 
interventions should still be implemented to promote successful smoking 
cessation.
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Figure 1. 
Schematic diagram on the selection of the study participants. NHANES III, Third National 
Health and Nutrition Examination Survey.
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Table 1
Selected demographic and clinical characteristics of the study participants*
Non-smokers (N=5761) Former smokers (N=2563) Current smokers (N=2679) p Value†
Age (years.) 41.8 (0.2)    52.2 (0.3)    42.2 (0.3)    <0.01
Men (n, %) 1833 (31.8)  1534 (59.9)  1344 (50.2)  <0.01
Race or ethnicity (n, %)
 Non-Hispanic white 1739 (30.2)  1227 (47.9)  986 (36.8)  <0.01
 Non-Hispanic black 1726 (30.0)  555 (21.7)  940 (35.1)  
 Mexican-American 1979 (34.4)  706 (27.5)  664 (24.8)  
 Other 317 (5.5)    75 (2.9)    89 (3.3)    
Annual household income (n, %)
 ≤$15,000 1670 (32.1)  649 (27.6)  983 (40.1)  <0.01
 $15,001–$25,000 1205 (23.1)  551 (23.5)  598 (24.4)  
 >$25,000 2331 (44.8)  1148 (48.9)  871 (35.5)  
Education (n, %)
 ≤8 years 1289 (22.5)  636 (24.9)  614 (23.1)  <0.01
 9–12 years 2604 (45.5)  1113 (43.6)  1527 (57.5)  
 >12 years 1828 (32.0)  801 (31.4)  516 (19.4)  
Body mass index (n, %)
 <25 kg/m2 2121 (36.9)  752 (29.4)  1181 (44.1)  <0.01
 25–30 kg/m2 1901 (33.1)  982 (38.4)  888 (33.2)  
 ≥30 kg/m2 1726 (30.0)  821 (32.1)  606 (22.7)  
Physical activity (n, %)
 Inactive 1907 (33.1)  749 (29.2)  920 (34.3)  <0.01
 Moderately active 2548 (44.2)  1300 (50.7)  1264 (47.2)  
 Active 1306 (22.7)  514 (20.1)  495 (18.5)  
Diabetes‡ (n, %) 777 (13.5)  456 (17.8)  356 (13.3)  <0.01
Hypertension‡ (n, %) 1396 (24.5)  858 (33.7)  602 (22.7)  <0.01
Hypercholesterolemia‡ (n, %) 928 (32.5)  656 (40.7)  383 (34.9)  <0.01
Glycosylated hemoglobin (%) 5.5 (0.02)  5.8 (0.03)  5.6 (0.02)  <0.01
Insulin resistance§ (n, %) 2127 (37.0)  1102 (43.0)  847 (31.7)  <0.01
Systolic BP (mm Hg) 121.7 (0.2)    128.6 (0.4)    122.0 (0.4)    <0.01
Diastolic BP (mm Hg) 73.7 (0.1)    76.2 (0.2)    73.7 (0.2)    <0.01
Serum triglycerides (mmol/L) 1.5 (0.02)  1.9 (0.03)  1.7 (0.03)  <0.01
Serum total cholesterol (mmol/L) 5.2 (0.02)  5.6 (0.02)  5.2 (0.02)  <0.01
Serum LDL cholesterol (mmol/L) 3.3 (0.02)  3.5 (0.03)  3.3 (0.03)  <0.01
Serum HDL cholesterol (mmol/L) 1.3 (0.005) 1.3 (0.008) 1.2 (0.008) <0.01
Serum alanine aminotransferase (U/L) 17.7 (0.2)    18.3 (0.3)    16.6 (0.3)    <0.01
Serum aspartate aminotransferase (U/L) 21.2 (0.2)    22.0 (0.2)    20.1 (0.2)    <0.01
Serum γ-glutamyltransferase (U/L) 28.3 (0.5)    33.6 (0.9)    32.2 (0.9)    <0.01
Serum uric acid (μmol/L) 300.4 (1.2)    335.0 (1.8)    310.1 (1.7)    <0.01
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Non-smokers (N=5761) Former smokers (N=2563) Current smokers (N=2679) p Value†
Serum cotinine (ng/mL)¶ 0.17±0.44          0.22±0.72          210.0±221.0          <0.01
Hepatic steatosis (n, %)
 None 3700 (64.2)  1454 (56.7)  1813 (67.7)  <0.01
 Mild 795 (13.8)  341 (13.3)  339 (12.7)  
 Moderate 862 (15.0)  514 (20.1)  372 (13.9)  
 Severe 404 (7.0)    254 (9.9)    155 (5.8)    
*Values are numbers (percentages) for categorical variables and means (SEs) for continuous variables.
†
From one-way ANOVA for continuous variables and χ2 test for categorical variables.
‡Self-reported doctor diagnosis.
§
Insulin resistance was defined as HOMA>3.0.
¶Values are medians±IQR.
ANOVA, analysis of variance; BP, blood pressure; HDL, high-density lipoprotein; HOMA, homeostasis of model assessment score; LDL, low-
density lipoprotein.
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